Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study.
Six chronic neuroleptic-resistant schizophrenic patients, partial responders to clozapine, were co-administered 600 mg/day of sulpiride (a selective D(2) dopaminergic antagonist) as an augmentation to clozapine (a relatively weak D(2) blocker), for 10 weeks, open-labeled. A remarkable reduction in positive and negative symptoms was observed in four of the six patients.
Shiloh
R
R
Zemishlany
Z
Z
Aizenberg
D
D
Weizman
A
A